DTI Inc.

Novel bispecific oligonucleotide therapeutics for the treatment of chronic inflammation/allergy

DTI Inc.

Novel bispecific oligonucleotide therapeutics<br>for the treatment of chronic inflammation/allergy

Novel bispecific oligonucleotide therapeutics
for the treatment of chronic inflammation/allergy

About Us

Research and Development

Contact

Recent News

2025.7.28

Dual Targets Inc. is pleased to announce that the Company has entered into a collaborative research agreement with Gifu University.
Under the agreement, Dual Targets Inc. and Gifu University will jointly investigate the pathophysiology of high endothelial venules and CHST2/4 in inflammatory skin diseases.


2025.2.27

Dual Targets Inc. announced the publication of a new patent application related to its proprietary technology, further strengthening the company’s intellectual property portfolio in the field of skin diseases.